ARTICLE | Finance
Finance Report: RA, Forbion back immunology play Navigator to develop bispecific
Plus: Series A for oncology play Noetik; China-based DualityBio files for Hong Kong IPO
August 30, 2024 5:45 PM UTC
Newly launched Navigator has drawn a $100 million series A round to advance a bifunctional molecule for immunological disorders, obtained via an in-licensing deal with a Korean biotech.
RA Capital Management and Forbion are backing Navigator Medicines Inc., which introduced itself with an announcement early Tuesday. The start-up’s bispecific antibody targeting OX40L and TNFα has already begun Phase I testing...